re other drugs and phases - as MSB has previously stated, TEVA are only committed, at this time, to Ph3 of the cardio treatment.
MSB has sufficient funds to currently progress its other trials etc on its own - it MAY, at some point in the future, seek partners for some/all of its other targeted fields (which may or may not include TEVA) - the market should hear more about the other studies underway in the first half of 2013.
Early assessment points in a Ph3 trial are pretty common - they cost over $100m, so they're always a BIG deal! It is a "fair comment" regards medical trials to say that, on balance, IF a treatment gets to Ph3 and - it maintains a good safety profile - it's looking good for success. Any medicos who monitor this thread, I'd welcome your thoughts on my general comment?
Again, if MSB can, in truth, deliver the type of products it wishes to, it'll have would-be partners lined up for miles - my own personal view, their T2D treatment (now in Ph2) is the [potential] waking giant for them - it will change the medical world - and given its success, so far, in large primate based studies it's looking very promising at this time - and given that health authorities desperately need genuine treatments in that growing space, it COULD be only 2/3yrs away - I believe, baring any "unforeseens" it alone is a front page news item in the making - and then there's the other treatments...MSB just requires a bit more patience, but she is stepping slowly out in to the clinical world.....
Cato, you mention a study you've read, do you have a source please, so we can keep this forum balanced and open to a cross-section of information?
- Forums
- ASX - By Stock
- MSB
- negative comments.
negative comments., page-12
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
98.5¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.136B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $1.984M | 1.981M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
29 | 67238 | 98.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.0¢ | 73386 | 44 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
30 | 72915 | 0.985 |
20 | 161885 | 0.980 |
9 | 102135 | 0.975 |
6 | 128232 | 0.970 |
9 | 619718 | 0.965 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 72488 | 43 |
0.995 | 58231 | 17 |
1.000 | 54452 | 11 |
1.005 | 66734 | 7 |
1.010 | 90341 | 5 |
Last trade - 14.16pm 15/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online